Yinfeng Cryogenic Medical Technology Co., Ltd. was listed on the list of "Innovative Small and Medium-sized Enterprises in Shandong Province in 2022".
Release time:
2022-12-31
On December 30, 2022, the Shandong Provincial Department of Industry and Information Technology announced the list of "Shandong Province 2022 Innovative Small and Medium-sized Enterprises", and Yinfeng Cryogenic Medical Technology Co., Ltd. (hereinafter referred to as "Yinfeng Cryological") won this honor.
The selection of "Shandong Province 2022 Innovative Small and Medium-sized Enterprises" aims to adhere to the improvement of the innovation ability and professional level of small and medium-sized enterprises, actively carry out the gradient cultivation of high-quality small and medium-sized enterprises, and continuously increase the support for various high-quality small and medium-sized enterprises.
In recent years, cryogenic biomedicine, as a forward-looking field of human medical research, is inseparable from the joint efforts of scientific research teams from all parties. Recently, the second expert committee of Yinfeng Cryogenic Medicine was formally established, bringing together 22 international and domestic experts and scholars from cryogenic biomedicine, cryopreservation of human tissues and organs, clinical scientific research, biomaterials science and other related fields, to carry out technology research and development and transformation of clinical achievements in the field of cryogenic biomedicine, build an academic exchange and achievement sharing platform for the global cryogenic biomedical research team, integrate international and domestic scientific research and academic forces in multiple fields, and build a systematic cryogenic biomedical research system. Contribute China's strength to the development of international cryogenic medicine.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
